A growing body of evidence suggests that Met pathway could function as a driving force for invasive growth and early metastasis of HNSCC, and may cooperate with EGFR to cause resistance against anti-EGFR therapy. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.